

学术搜索

找到约 3,390 条结果 (用时0.13秒)

文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

英语网页

 包括专利 包含引用 创建快讯**Phase II study of sorafenib in patients with advanced hepatocellular carcinoma**

GK Abou-Alfa, L Schwartz, S Ricci... - Journal of Clinical ..., 2006 - jco.ascopubs.org

... Several **biomarkers** have been shown to have potential **predictive** significance in HCC. ... based and genomic analyses will undoubtedly advance the discovery of new **biomarkers** for HCC ... developed by Pugh and later revised by Child, which help in **predicting** prognostic outcome ...

被引用次数: 1046 相关文章 所有 9 个版本 引用 保存

ascopubs.org 中的 [HTML]

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

AX Zhu, DV Sahani, DG Duda... - Journal of Clinical ..., 2009 - jco.ascopubs.org

... identification of mechanism of drug action and **biomarkers** capable of **predicting tumor** response and ... Thus, the **predictive** value of imaging **biomarkers** remains to be standardized and ... we show that sunitinib treatment significantly changed multiple angiogenic **biomarkers** in HCC ...

被引用次数: 365 相关文章 所有 8 个版本 引用 保存

ascopubs.org 中的 [HTML]

Sorafenib in advanced hepatocellular carcinoma

JM Llovet, S Ricci, V Mazzaferro... - New England journal ..., 2008 - Mass Medical Soc

... **Sorafenib** (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals) is a small molecule that inhibits **tumor-cell** ... CI], 0.55 to 0.87; P<0.001) (Table 2Table 2 Summary of **Efficacy** Measures. ... Phase II study of **sorafenib** in patients with **advanced hepatocellular carcinoma** ...

被引用次数: 4799 相关文章 所有 12 个版本 引用 保存

researchgate.net 中的 [PDF]

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

BI Rini, B Escudier, P Tomczak, A Kaprin, C Szczylik... - The Lancet, 2011 - Elsevier

... So far, no phase 3 randomised trials comparing the **effectiveness** of one targeted agent against another have been ... Summary of **efficacy** measures in intention-to-treat population. ... **Sorafenib** (n=362), HR for progression or death (95% CI), p value, Axitinib (n=361), **Sorafenib** (n=362 ...

被引用次数: 704 相关文章 所有 8 个版本 引用 保存

cadmus.com 中的 [PDF]

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study

S Faivre, E Raymond, E Boucher, J Douillard, HY Lim... - The lancet oncology, 2009 - Elsevier

... or mixed histology; previous systemic therapy for HCC including **sorafenib**; previous local ... its equipotent metabolite, SU012662; and exploration of soluble plasma **biomarkers** of response. ... Statistical analysis of **biomarker** data included significance tests (two-sample Student's t ...

被引用次数: 232 相关文章 所有 11 个版本 引用 保存

udea.edu.co 中的 [PDF]

Name of journal: *World Journal of Gastroenterology*

ESPS Manuscript NO: 17786

Columns: TOPIC HIGHLIGHT

Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?

Shao YY *et al.* Predictive biomarkers for sorafenib

Yu-Yun Shao, Chih-Hung Hsu, Ann-Lii Cheng

Yu-Yun Shao, Chih-Hung Hsu, Ann-Lii Cheng, Graduate Institute of Oncology, National Taiwan University College of Medicine, Taipei 10051, Taiwan

Yu-Yun Shao, Chih-Hung Hsu, Department of Oncology, National Taiwan University Hospital, Taipei 10002, Taiwan

Match Overview

1 **Internet** 92 words
crawled on 09-Mar-2015
www.researchgate.net

1%

学术搜索

找到约 3,590 条结果 (用时0.11秒)

文章

我的图书馆

时间不限

2015以来

2014以来

2011以来

自定义范围...

按相关性排序

按日期排序

搜索所有网页

中文网页

英语网页

 包括专利 包含引用 创建快讯**Phase II study of sorafenib in patients with advanced hepatocellular carcinoma**

GK Abou-Alfa, L Schwartz, S Ricci,... - Journal of Clinical ..., 2006 - jco.ascopubs.org

... Several **biomarkers** have been shown to have potential **predictive** significance in HCC. ... based and genomic analyses will undoubtedly advance the discovery of new **biomarkers** for HCC ... developed by Pugh and later revised by Child, which help in **predicting** prognostic outcome ...

被引用次数: 1092 相关文章 所有 7 个版本 引用 保存

ascopubs.org 中的 [HTML]

Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study

AX Zhu, DV Sahani, DG Duda... - Journal of Clinical ..., 2009 - jco.ascopubs.org

... identification of mechanism of drug action and **biomarkers** capable of **predicting tumor** response and ... Thus, the **predictive** value of imaging **biomarkers** remains to be standardized and ... we show that sunitinib treatment significantly changed multiple angiogenic **biomarkers** in HCC ...

被引用次数: 380 相关文章 所有 8 个版本 引用 保存

ascopubs.org 中的 [HTML]

Sorafenib in advanced hepatocellular carcinoma

JM Llovet, S Ricci, V Mazzaferro... - ... England Journal of ..., 2008 - Mass Medical Soc

... **Sorafenib** (Nexavar, Bayer HealthCare Pharmaceuticals–Onyx Pharmaceuticals) is a small molecule that inhibits tumor-cell ... CI], 0.55 to 0.87; P<0.001) (Table 2Table 2 Summary of Efficacy Measures, ... Phase II study of **sorafenib** in patients with **advanced hepatocellular carcinoma** ...

被引用次数: 5164 相关文章 所有 9 个版本 引用 保存

researchgate.net 中的 [PDF]

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

BI Rini, B Escudier, P Tomczak, A Kaprin, C Szczylik... - The Lancet, 2011 - Elsevier

... So far, no phase 3 randomised trials comparing the **effectiveness** of one targeted agent against another have been ... Summary of **efficacy** measures in intention-to-treat population. ... **Sorafenib** (n=362), HR for progression or death (95% CI), p value, Axitinib (n=361), **Sorafenib** (n=362 ...

被引用次数: 764 相关文章 所有 9 个版本 引用 保存

cadmus.com 中的 [PDF]

Management of hepatocellular carcinoma: an update

J Bruix, M Sherman - Hepatology, 2011 - Wiley Online Library

... Independent risk factors and **predictive** score for the development of **hepatocellular carcinoma** in chronic ... Des-gamma-carboxy prothrombin and alpha-fetoprotein as **biomarkers** for the early detection of ... **Efficacy** and safety of **sorafenib** in patients in the Asia-Pacific region with ...

被引用次数: 2689 相关文章 所有 98 个版本 引用 保存

wiley.com 中的 [HTML]

Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open

researchgate.net 中的 pdf

[网页](#) [新闻](#) [图片](#) [视频](#) [购物](#) [更多 ▾](#) [搜索工具](#)

找到约 112,000 条结果 (用时 0.24 秒)

Google 学术 : Predictive biomarkers of sorafenib efficacy in advanced hepatocellular carcinoma: Are we getting there?

... in patients with advanced hepatocellular carcinoma - Abou-Alfa - 被引用次数 : 1102

... in advanced hepatocellular carcinoma: a phase II ... - Zhu - 被引用次数 : 386

Sorafenib in advanced hepatocellular carcinoma - Llovet - 被引用次数 : 5227

Predictive biomarkers of antiangiogenic therapy for ...

www.ncbi.nlm.nih.gov/pubmed/24159601 - [翻译此页](#)

作者 : YY Shao - 2013 - 被引用次数 : 14 - [相关文章](#)

Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? ... pivotal phase III study of sorafenib (the SHARP study) and did not find any plasma markers that could predict the efficacy of sorafenib.

Predictive Biomarkers of Antiangiogenic Therapy for ...

www.bioportfolio.com > Citations > Liver cancer ▾ [翻译此页](#)

The poor prognosis of hepatocellular carcinoma (HCC) and the lack of specific ... between adverse events (AEs), efficacy, and nursing intervention for sorafenib therapy ... Drug Monitoring of Sorafenib in Patients With Advanced Hepatocellular Carcinoma ... Therapy for Advanced Hepatocellular Carcinoma: Where Are We?

^[PDF] Chemotherapy for advanced hepatocellular carcinoma in ...

www.wjgnet.com/1007-9327/pdf/v20/i15/4151.pdf ▾ [翻译此页](#)

作者 : K Miyahara - 2014 - 被引用次数 : 9 - [相关文章](#)

2014年4月21日 - patients with advanced hepatocellular carcinoma (HCC). ... biomarkers predicting sorafenib efficacy are the most important issues ... ing conventional characteristics of patients, there are ... we have done extensive literature